Publications by authors named "Moses Owoicho Abah"
A thorough study of Clear Cell Renal Cell Carcinoma (ccRCC) shows that combining tyrosine kinase inhibitors (TKI) with immune checkpoint inhibitors (ICI) shows promising results in addressing the tumor-promoting influences of abnormal immunological and molecular biomarkers in metastatic Clear Cell Renal Cell Carcinoma (ccRCC). These abnormal biomarkers enhance drug resistance, support tumor growth, and trigger cancer-related genes. Ongoing clinical trials are testing new treatment options that appear more effective than earlier ones.
View Article and Find Full Text PDFArticle Synopsis
- Research indicates that growth factors play a significant role in lung cancer angiogenesis, which helps tumors grow and spread by affecting the immune response.
- New treatment strategies focus on developing anti-angiogenic compounds that block the activity of these growth factors, particularly EGF and VEGF, to hinder lung cancer progression.
- While the initial results of these therapies are promising, there is a heightened risk of toxicity, necessitating personalized follow-up care for patients undergoing treatment.